{"id":1194,"date":"2024-04-05T11:48:00","date_gmt":"2024-04-05T11:48:00","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-has-submitted-application-for-cross-trading-at-otcqb-in-the-us\/"},"modified":"2024-08-06T12:23:52","modified_gmt":"2024-08-06T12:23:52","slug":"acarix-has-submitted-application-for-cross-trading-at-otcqb-in-the-us","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-has-submitted-application-for-cross-trading-at-otcqb-in-the-us\/","title":{"rendered":"Acarix has submitted application for cross-trading at OTCQB in the US"},"content":{"rendered":"
\n

New York, New York, April 5, 2024 \u2013 Acarix, a leader in advanced acoustic-based cardiac diagnostics announces the submission of an application for cross-trading of the Acarix share on the OTCQB trading platform. Upon approval, Acarix shares will in parallel to its current First North Growth Market listing, be traded with a US ticker symbol and a share price in USD.<\/strong><\/p>\n<\/div>\n

\n

OTCQB is a trading platform in the United States operated by the OTC Markets Group, as an alternative to listing on Nasdaq New York and NYSE. Cross-trading on OTCQB helps satisfy an increasing interest from US investors and increase accessibility to the US capital market. Upon approval, Acarix shares will be traded with a US ticker symbol and a share price in USD, during US market hours.<\/p>\n

"After registration of the latest directed share issue, around 20 percent of the shares in Acarix are held by US investors, and our commercial focus is on the US market. As a result, we want to make it easier for US investors to trade in the Acarix share\u201d, comments Aamir Mahmood, CEO of Acarix AB.<\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com<\/a>\u00a0<\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Acarix has submitted application for cross-trading at OTCQB in the US<\/a><\/p>\n<\/div>\n